* The full-dose regimen of GeoVax vaccines continues to be well
tolerated without any type of reaction, mild or systemic, in the
majority of participants
* CD4 T-cell responses are high in both the low and full-dose
regimens, 84% and 78% of participants
* CD8 T-cell responses are present in 42% of the full-dose
recipients and 33% of the 1/10th dose recipients.
* Antibody responses to the envelope glycoprotein (Env) increased
following the fourth vaccination, and were present in 88% of the
* Delivery of the fourth vaccination increased the frequency and
magnitude of the CD8 T-cell and Antibody responses
-- In November, GeoVax filed a Form 8-K with the SEC disclosing that it
was unlikely to receive the full amount of its previously announced
$7.5 million equity placement with Pure Capital LLC ("Pure"). The
Company received $300,000 from Pure during September, but Pure appeared
to be unable to fulfill its commitment for the remaining $7.2 million.
GeoVax has already initiated contacts with alternative sources of
equity capital and preliminary discussions with prospective investors
are promising. However, the Company can provide no assurance that such
other sources of equity capital will be available on favorable terms,
if at all.
Donald Hildebrand, Chief Executive Officer of GeoVax, commented, "We
continue to be excited about the promise of our AIDS vaccine technology. We
are particularly encouraged by the recent $15 million grant award from the
NIH, which we view as a strong validation of the prospects for our vaccine.
We also are very pleased with the additional positive results we've seen
for both our full and 1/10th dose groups in our Phase I hum
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved